Compare Mesoblast Limited (MESO) vs State Street PDR S&P Retail ETF (XRT) Price & Performance

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

XRT trades at $88.94, down 0.54% today, with a bullish technical outlook from moving averages but neutral oscillators. Recent retail sales data shows five consecutive months of growth, supporting the ETF's consumer discretionary exposure. The fund offers diversified retail sector access but lacks specific valuation metrics in current data.

The ETF benefits from sustained consumer spending trends but faces headwinds from inflation and weak sentiment. Technical strength suggests near-term upside potential, though overbought RSI signals caution. Risks include macroeconomic pressures and sector volatility.